Selank 5mg For Anti-anxiety And Nootropic CAS:129954-34-3

     What is Selank? The Molecular Foundation

     Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a heptapeptide designed in Russia, retaining Tuftsin's immunomodulatory core (Thr-Lys-Pro-Arg) while adding a Gly-Pro-Pro sequence believed to enhance stability, blood-brain barrier penetration, and potentially confer anxiolytic and nootropic properties distinct from its parent molecule. Unlike traditional benzodiazepines targeting GABA-A receptors directly, Selank's primary mechanism is subtler and more systemic:

    ●Modulation of GABAergic Systems: It influences the expression and function of GABA (the brain's primary inhibitory neurotransmitter) receptors and potentially enhances GABA synthesis/release, promoting calm without the pronounced sedation or addiction liability of benzos.

    ●Serotonergic Influence: Evidence suggests interaction with the serotonin (5-HT) system, particularly 5-HT1A receptors, contributing to mood stabilization and anxiety reduction.

    ●BDNF Enhancement: Selank may increase Brain-Derived Neurotrophic Factor (BDNF), crucial for neuronal survival, plasticity, learning, and memory – underpinning its nootropic potential.

    ●Immune System Regulation: Inheriting Tuftsin's legacy, Selank exhibits immunomodulatory effects, potentially mitigating stress-induced immune suppression. The brain-immune axis is increasingly recognized in mood disorders.

    ●Stress Hormone Attenuation: It appears to modulate the HPA (Hypothalamic-Pituitary-Adrenal) axis, potentially reducing excessive cortisol release associated with chronic stress and anxiety.

 

 

    Using Selank at 5mg fundamentally alters its profile compared to standard doses:

    ●Magnitude of Effect: The most obvious feature is the potential for dramatically amplified effects – significantly stronger anxiolysis and potentially more pronounced cognitive impacts (both positive and negative).

    ●Dose-Response Curve Uncertainty: Peptides often exhibit complex, non-linear dose-response relationships. Effects seen at 500mcg may not simply scale linearly to 5mg. New effects might emerge, desired effects might plateau or even reverse (inverted U-curve), and side effects could become dominant.

    ●Receptor Saturation & Spillover: At 5mg, Selank likely achieves near-complete saturation of its primary high-affinity targets (e.g., specific GABA receptor subtypes, 5-HT1A). This forces interaction with lower-affinity secondary targets, leading to unpredictable "spillover" effects unrelated to its intended primary mechanisms.

    ●Increased Metabolic Load: The body must metabolize and clear ten times the typical dose. This places significant strain on enzymatic pathways (e.g., peptidases) and clearance organs (kidneys, liver), potentially altering pharmacokinetics and increasing metabolite accumulation.

    ●Heightened Risk of Immunomodulatory Effects: While generally mild at standard doses, the potent immunomodulatory action becomes a major consideration at 5mg. The risk of triggering undesirable immune responses (e.g., excessive cytokine release, autoimmunity flares) increases substantially.

    ●Novel Side Effect Profile: Side effects manageable or absent at lower doses (e.g., mild transient hypotension, fatigue, headache) could become severe. New, dose-specific adverse reactions are highly probable but undocumented.

    The rationale for exploring 5mg exists in theory, but is fraught with peril:

    ●Treatment-Resistant Severe Anxiety: The primary hypothetical application. For individuals with debilitating anxiety disorders unresponsive to conventional therapies (SSRIs, SNRIs, benzos, therapy) and standard Selank doses, 5mg might offer a last-resort level of relief. This is purely speculative.

    ●Acute Crisis Intervention: Analogous to high-dose benzos for panic attacks, a single 5mg dose might be theorized for rapid, profound calming in extreme, acute anxiety states. However, its onset (15-45 mins SC/IM, slower IN) isn't as rapid as some fast-acting benzos.

    ●Potentiated Nootropic Effects: Could the cognitive benefits (focus, memory, mental clarity) seen at lower doses be exponentially greater? Possibly, but equally likely is cognitive impairment due to excessive GABAergic inhibition (brain fog, sedation). Enhanced BDNF release might offer stronger neuroprotective or plasticity effects.

    ●Accelerated Adaptation: In extreme stress environments (theoretical, e.g., combat, deep space), such a dose might be explored to forcibly downregulate stress responses rapidly. The long-term consequences would be unknown.

    The risks escalate dramatically and are the defining characteristic of this dose:

    ●Profound Sedation & Cognitive Impairment: Excessive GABAergic activity is highly likely to cause severe drowsiness, sluggish thinking, impaired reaction times, and brain fog – counteracting any potential nootropic benefit and posing dangers (e.g., driving).

    ●Hypotension: Significant drops in blood pressure, leading to dizziness, lightheadedness, fainting, and falls, are a major concern.

    ●Paradoxical Reactions: High doses of GABAergics can sometimes trigger increased anxiety, agitation, irritability, or even panic attacks in susceptible individuals.

    ●Immune System Dysregulation: Risk of inducing excessive inflammation (cytokine storm-like effects) or suppressing immunity too much, increasing infection susceptibility. Potential to trigger or worsen autoimmune conditions.

    ●HPA Axis Disruption: While modulation is a goal, excessive suppression could lead to adrenal insufficiency-like symptoms or rebound hyperactivity after cessation.

    ●Uncharacterized Organ Stress: Impact on liver/kidney function at this dose is unknown but concerning.

    ●Tachyphylaxis & Dependence: Rapid tolerance development is highly probable, requiring even higher doses for effect, escalating risks. While physical dependence like benzos is unlikely, psychological dependence is possible. Rebound anxiety upon cessation could be severe.

    ●Drug Interactions: Risk of dangerous interactions (e.g., profound CNS depression with alcohol, opioids, sedatives; amplified hypotension with blood pressure meds) is extremely high.

    ●Lack of Reversal Agent: Unlike benzodiazepines (flumazenil), there is no specific antidote for Selank overdose.

    ●Dose: 5mg (5000 mcg) per administration. This is experimental and not standard practice.

    ●Route:

    ○Subcutaneous (SC) Injection: Most common for precise dosing. Requires sterile technique. Rotate injection sites.

    ○Intramuscular (IM) Injection: Faster absorption than SC, potentially quicker onset. Higher risk of local reaction.

    ○Intranasal (IN): Convenient, but bioavailability is lower and highly variable (estimates 30-60%). Achieving a consistent 5mg dose nasally is impractical (requires large volume) and risks local irritation/systemic absorption issues. Not recommended for 5mg.

    ○Oral: Very low bioavailability due to digestion. Ineffective.

    ●Frequency: If used at all, frequency would likely be significantly reduced compared to standard doses – potentially only once daily or even less frequently (e.g., every other day, or only during acute crises) due to long half-life and risk accumulation. Daily use drastically increases risk profiles.

    Cycling is mandatory at this dose to attempt to mitigate tolerance and side effects:

    ●"Pulse" Approach: Given the dose intensity, cycles would likely be very short. Example: 3 days ON, 4 days OFF. Or single doses only for acute crises with significant rest periods in between.

    ●Duration: Continuous use beyond 7-10 days at this dose is strongly discouraged due to rapidly escalating risks (tolerance, side effects, potential immune/HPA disruption).

    ●Post-Cycle: Allow ample time (weeks) for receptor reset, HPA axis normalization, and metabolite clearance before considering another cycle. Monitor for rebound anxiety.

    ●Half-Life: Selank's half-life is estimated to be approximately 30-60 minutes based on animal studies and limited human data at standard doses. This is a critical point of uncertainty at 5mg.

    ●5mg Implications:

    ○Metabolic Saturation: Enzymes responsible for breaking down Selank may become saturated at 5mg, leading to a prolonged half-life. Instead of 30-60 mins, it could extend to several hours or more.

    ○Accumulation Risk: With a potentially prolonged half-life and high dose, significant accumulation in the body is likely, especially with repeated dosing, even spaced out. This amplifies all risks (sedation, hypotension, immune effects) over time.

    ○Extended Duration of Action: While the acute peak effects might last several hours (like lower doses), the total clearance time for the massive 5mg dose could be many hours or even over a day, leading to prolonged low-level effects and interactions.

Trade names	Selanc; Selangke, Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP)
CAS	129954-34-3
Molar mass	751.887
Formula	C33H57N11O9
Purity	Above 98%
Apprarance	5mg/vial,Lyophilized powder

 

 

Any needs, please contact us

Email: Jasonraws106@gmail.com

WhatsApp: +86-15572565525
Telegram: +86-15871669785

   

                                   

 

    Selank at 5mg represents an extreme, experimental departure from established use. While theoretically offering profound anxiolysis or nootropic effects for the most severe, treatment-resistant cases, the risks are immense, multifaceted, and poorly characterized. The potential for severe sedation, dangerous hypotension, immune dysregulation, paradoxical reactions, rapid tolerance, and unpredictable pharmacokinetics overshadows any hypothetical benefit.

    This dose should only be considered, if at all, under strict medical supervision within a formal research setting by individuals fully aware of and prepared to accept the significant hazards. It is emphatically not suitable for casual experimentation or self-administration based on anecdotal reports. The vast majority of users seeking Selank's benefits will find the well-documented, significantly safer profile of doses in the 250-750mcg range far more appropriate and effective. The 5mg dose exists on the fringes of peptide pharmacology, a stark reminder that "more" is rarely better in neurochemistry, and venturing into uncharted high-dose territory carries profound and potentially irreversible consequences. Responsible exploration prioritizes safety and adheres to the principle of using the minimum effective dose.

Hot Tags: selank 5mg for anti-anxiety and nootropic cas:129954-34-3, China selank 5mg for anti-anxiety and nootropic cas:129954-34-3 manufacturers, suppliers, factory